Seeking Alpha
  • Wednesday, October 22, 2014

  • 7:11 PM
    • MSA Safety (NYSE:MSA): Q3 EPS of $0.57 beats by $0.02.
    • Revenue of $275.7M (+3.8% Y/Y) beats by $1.05M.
    | Comment!
  • 6:38 PM
    • IPC The Hospitalist (IPCM -0.4%) Q3 results: Revenues: $169.8M (+13.9%); Operating Expense: $155.5M (+15.8%); Operating Income: $14.3M (-3.4%); Net Income: $8.6M (-5.5%); EPS: $0.49 (-5.8%); Quick Assets: $25.5M (+2.0%); CF Ops: $53.8M (+15.5%).
    • 2014 Guidance: Revenues: $692M - $698M from $720M - $732M; EPS: $2.23 - $2.29 from $2.41 - $2.51, EBITDA: $71.0M - $72.5M from $76.0M - $79.0M.
    | Comment!
  • 5:59 PM
    • Sangamo BioSciences (SGMO -1.7%) Q3 results: Revenues: $169.8M (+13.9%); Collaboration Agreements: $12.0M (+149.6%) Operating Expenses: $20.1M (+68.9%); Operating Loss:($7.7M) (-24.2%); Net Loss: ($7.5M) (-22.8%); EPS: ($0.11) (unch); Quick Assets: $231.8M (+75.9%).
    • 2014 Guidance: Revenues: $45M - $50M; Operating expenses: $70M - $75M from $65M - $70M; Quick Assets: at least $220M by year end from $225M.
    | Comment!
  • 5:45 PM
    • Alkermes (ALKS +2%) will report Q3 results on October 29 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is EPS of $0.02 on revenues of $156M.
    | Comment!
  • 5:34 PM
    • Tesaro (TSRO -1.2%) will report Q3 results on November 5 after the close. The conference call will begin at 4:15 pm ET.
    • Consensus view is a loss of ($1.04).
    | Comment!
  • 5:30 PM
    • Lightly-traded nano cap Alcobra (NASDAQ:ADHD) slumps 13% AH on higher-than-average volume in response to a presentation of results from a Phase 2b clinical trial evaluating Metadoxine (vitamin B6 and L-PGA) for the treatment of attention deficit/hyperactivity disorder given by Dr. Lenard Adler at the American Academy of Child & Adolescent Psychiatry Meeting in San Diego.
    • On Slide 26, the graph shows that Metadoxine failed to demonstrate statistically significant efficacy compared to placebo at week six (p=0.136). This was the study's primary endpoint.
    | 2 Comments
  • 5:09 PM
    • Varian Medical Systems (VAR +0.2%) fiscal Q4 and full-year results ($M):
    • Fiscal Q4: Revenues: 812.1 (+5.6%); Gross Profit: 340.1 (+3.5%); Operating Expenses: 180.9 (+8.0%); Operating Income: 159.2 (-1.1%); Net Income: 105.9 (-9.7%); EPS: 1.02 (-5.6%); Quick Assets: 915.5 (-22.5%).
    • Gross Orders: 1,154.0 (+10.7%), Oncology Systems: 917.7 (+9.1%), Imaging Components: 233.8 (+11.8%). Net Orders: 1,112.9 (+25.6%); Oncology Systems: 880.4 (+28.5%); Imaging Components: 230.0 (+14.3%).
    • Fiscal 2014: Revenues: 3,049.8 (+3.6%); Gross Profit: 1,301.7 (+4.2%); Operating Expenses: 705.4 (+10.1%); Operating Income: 571.2 (-6.2%); Net Income: 403.7 (-7.9%); EPS: 3.83 (-3.8%).
    • Gross Orders: 3,527.3 (+9.4%), Oncology Systems: 2,684.4 (+5.1%), Imaging Components: 722.5 (+8.1%). Net Orders: 3,351.0 (+12.9%), Oncology Systems: 2,520.8 (+9.6%), Imaging Components: 710.7 (+6.7%).
    • Order Backlog: 3,170.2 (+10.5%).
    • 2015 Guidance: Revenue growth: 5 - 6%; EPS: $4.16 - 4.26.
    • Fiscal Q1 Guidance: Revenue growth: 0 - 2%; EPS: $0.76 - 0.80.
    | Comment!
  • 4:32 PM
    • C.R. Bard (BCR -0.9%) Q3 results ($M): Revenues: 830.0 (+9.5%); Gross Profit: 521.1 (+11.8%); Operating Expenses: 315.1 (-2.5%); Operating Income: 180.3 (+51.5%); Net Income: 131.3 (+40.9%); EPS: 1.69 (+47.0%).
    • Revenues by Product Group: Vascular: 231.5 (+10.3%); Urology: 209.6 (+8.2%); Oncology: 229.7 (+6.6%); Surgical Specialties: 135.6 (+14.8%); Other: 23.6 (+13.5%).
    • No financial guidance given.
    | Comment!
  • 4:28 PM
    • IPC The Hospitalist (NASDAQ:IPCM): Q3 EPS of $0.57 misses by $0.03.
    • Revenue of $169.76M (+13.9% Y/Y) misses by $8.43M.
    • Press Release
    | Comment!
  • 4:20 PM
    • Varian Medical Systems (NYSE:VAR): FQ4 EPS of $1.02 misses by $0.19.
    • Revenue of $812.1M (+5.5% Y/Y) misses by $34.4M.
    • Shares -3.98% AH.
    • Press Release
    | Comment!
  • 4:12 PM
    • C. R. Bard (NYSE:BCR): Q3 EPS of $2.15 beats by $0.05.
    • Revenue of $830M (+9.5% Y/Y) beats by $11.12M.
    • Press Release
    | Comment!
  • 4:08 PM
    • Sangamo BioSciences (NASDAQ:SGMO): Q3 EPS of -$0.11 beats by $0.03.
    • Revenue of $12.42M (+117.5% Y/Y) beats by $4.15M.
    • Press Release
    | Comment!
  • 1:29 PM
    • Fresenius Medical Care (FMS -0.2%) acquires National Cardiovascular Partners (NCP) for an undisclosed sum. The company expects the acquisition to add more than $200M to the top line in 2015 and be accretive to earnings in the first year after closing.
    • NCP is a leading operator of endovascular, vascular and cardiovascular services in the outpatient setting. It partners with over 200 doctors in 21 outpatient vascular centers in six states.
    | Comment!
  • 12:49 PM
    • Hedge fund manager Dan Loeb's bullish thesis on Amgen (AMGN -1.4%) relies on a break-up of the company into two separate organizations, one that would sell its legacy drugs and one that would focus on developing its pipeline. The idea was originally proposed by Sanford Bernstein's Geoffrey Porges in June.
    • Mr. Loeb believes that the split would increase the company's value ~80% or to ~$249 per share. He says that the market has penalized Amgen for three reasons: lack of R&D productivity, flat operating margins and the suspension of its share repurchase program. He also states that the market appears to be ignoring the disruptive potential of some of the firm's new products, like evolocumab for the treatment of dyslipidemia.
    • Amgen CEO Bob Bradway appears open-minded to the idea. The company has a business review meeting scheduled for October 28.
    | Comment!
  • 12:24 PM
    • In response to the changes in the tax code related to inversions, Abbott (ABT -1.1%) and Mylan (MYL -2.5%) adjust the terms of their $5.3B all-stock deal. The pricing terms related to product manufacturing and supply have been changed in favor of New Mylan and the number of shares of stock to be issued to Abbott have been increased to 110M from 105M.
    • Former shareholders of Mylan will own ~78% of New Mylan and Abbott and its affiliates will own ~22%. The transaction is expected to close in Q1 2015.
    | Comment!
  • 12:08 PM
    • Merge Healthcare (MRGE -3.9%) will report Q3 results on October 29 before the open. The conference call will begin at 7:30 am CT/8:30 am ET.
    • Consensus view is EPS of $0.03 on revenues of $53.6M.
    | Comment!
  • 12:04 PM
    • Evogene (EVGN -0.1%) will report Q3 results on November 10 before the open. The conference call will begin at 9:30 am ET.
    • Consensus view is a loss of ($0.11) on revenues of $4.2M.
    | Comment!
  • 11:59 AM
    • Momenta Pharmaceuticals (MNTA -0.9%) will report Q3 results on November 5 before the open. The conference call will begin at 10:00 am ET.
    • Consensus view is a loss of ($0.43) per share on revenues of $13M.
    | Comment!
  • 11:56 AM
    • LDR Holding Corp. (LDRH -0.4%) will report Q3 results on November 5 after the close. The conference call will begin at 4:00 pm CT/5:00 pm ET.
    • Consensus view is a loss of ($0.21) per share on revenues of $32M.
    | Comment!
  • 11:53 AM
    • ChemoCentryx (CCXI +1.1%) will report Q3 results on November 5 after the close. The conference call will begin at 2:00 pm PT/5:00 pm ET.
    • Consensus view is a loss of ($0.28) per share.
    | Comment!
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector